Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
Номер патента: CA2909952A1
Опубликовано: 06-11-2014
Автор(ы): Adam W. Clarke, Anthony G. Doyle, Collette Behrens, David S. Wilson, JR., Matthew Pollard, Sarah L. Pogue, Tetsuo Yamagishi, Tetsuya Taura
Принадлежит: TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
Опубликовано: 06-11-2014
Автор(ы): Adam W. Clarke, Anthony G. Doyle, Collette Behrens, David S. Wilson, JR., Matthew Pollard, Sarah L. Pogue, Tetsuo Yamagishi, Tetsuya Taura
Принадлежит: TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
Реферат: Antibodies that specifically bind to CD38, as well as constructs comprising such antibodies fused to attenuated interferon alpha-2B proteins are provided. Anti-CD38-attenuated interferon alpha-2b fusion constructs may be used to inhibit proliferation in cancerous cells that express both CD38 and the receptor for IFN-alpha2b, as well as to induce apoptosis in such cells. Inhibition of proliferation and induction of apoptosis in cancerous cells may serve as the basis for the treatment of the underlying cancer.
Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
Номер патента: NZ713641A. Автор: David Wilson,Adam Clarke,Matthew Pollard,Collette Behrens,Tetsuo Yamagishi,Tetsuya Taura,Anthony Doyle,Sarah Pogue. Владелец: TEVA PHARMACEUTICALS AUSTRALIA PTY LTD. Дата публикации: 2019-08-30.